Incidence of Cardiovascular Disease in Patients with Familial Hypercholesterolemia Phenotype: Analysis of 5 Years Follow-Up of Real-World Data from More than 1.5 Million Patients
dc.contributor.author
dc.date.accessioned
2019-09-04T10:30:02Z
dc.date.available
2019-09-04T10:30:02Z
dc.date.issued
2019-07-23
dc.identifier.uri
dc.description.abstract
In the statin era, the incidence of atherosclerotic cardiovascular diseases (ASCVD) in patients with familial hypercholesterolemia (FH) has not been updated. We aimed to determine the incidence of ASCVD in patients with FH-phenotype (FH-P) and to compare it with that of normal low-density lipoprotein cholesterol (LDL-C) patients. We performed a retrospective cohort study using the Database of the Catalan primary care system, including ≥18-year-old patients with an LDL-C measurement. From 1,589,264 patients available before 2009, 12,823 fulfilled FH-P criteria and 514,176 patients were normolipidemic (LDL-C < 115 mg/dL). In primary prevention, patients with FH-P had incidences of ASCVD and coronary heart disease (CHD) of 14.9/1000 and 5.8/1000 person-years, respectively, compared to 7.1/1000 and 2.1/1000 person-years in the normolipidemic group. FH-P showed hazard ratio (HR) of 7.1 and 16.7 for ASCVD and CHD, respectively, in patients younger than 35 years. In secondary prevention, patients with FH-P had incidences of ASCVD and CHD of 89.7/1000 and 34.5/1000 person-years, respectively, compared to 90.9/1000 and 28.2/1000 person-years in the normolipidemic group (HR in patients younger than 35 years: 2.4 and 6.0). In the statin era, FH-P remains associated with high cardiovascular risk, compared with the normolipidemic population. This excess of risk is markedly high in young individuals
dc.description.sponsorship
This project was supported by the Spain’sMinistry of Science and Innovation through the Carlos III Health
Institute co-financed with European Union ERDF funds (Network for Prevention and Health Promotion in primary
Care (RedIAPP RD16/0007/0004); the Red de Investigación Cardiovascular (RD12/0042/0061, RD12/0042/0013) and
CIBERCV; and by the Agency for Management of University and Research Grants of the Generalitat de Catalunya
[2017 SGR 1146] and [2017 SGR 222] and through the Agència de Qualitat i Avaluació Sanitàries de Catalunya, Pla
estratègic de recerca i innovació en Salut (PERIS) [SLT002/16/00145, SLT006/17/00029]
dc.format.mimetype
application/pdf
dc.language.iso
eng
dc.publisher
MDPI (Multidisciplinary Digital Publishing Institute)
dc.relation.isformatof
Reproducció digital del document publicat a: https://doi.org/10.3390/jcm8071080
dc.relation.ispartof
Journal of Clinical Medicine, 2019, vol. 8, núm. 7, p. 1080
dc.relation.ispartofseries
Articles publicats (D-CM)
dc.rights
Attribution 4.0 International
dc.rights.uri
dc.subject
dc.title
Incidence of Cardiovascular Disease in Patients with Familial Hypercholesterolemia Phenotype: Analysis of 5 Years Follow-Up of Real-World Data from More than 1.5 Million Patients
dc.type
info:eu-repo/semantics/article
dc.rights.accessRights
info:eu-repo/semantics/openAccess
dc.type.version
info:eu-repo/semantics/publishedVersion
dc.identifier.doi
dc.identifier.idgrec
030063
dc.type.peerreviewed
peer-reviewed
dc.identifier.eissn
2077-0383